Mutations in TP53 occur in more than 50% of the lung cancer patients and are associated with an increased resistance to chemotherapy and radiotherapy. The human lung adenocarcinoma cell lines A549 and LXSN contain a wild-type TP53 and were growth arrested at both the G(1)- and G(2)-phase checkpoints after irradiation. However, a TP53-disrupted cell line, E6, was arrested only at the G(2)-phase checkpoint. UCN-01 (7-hydroxystaurosporine), a CHEK1 inhibitor that abrogates the G(2) block, has been reported to enhance radiation toxicity in human lymphoma and colon cancer cell lines. In this study, UCN-01 preferentially enhanced the radiosensitivity of the TP53-disrupted E6 cells compared to the TP53 wildtype cells. This effect was more pronounced in cells synchronized in early G(1) phase, where the E6 cells showed a higher resistance to radiation in the absence of drug. These results indicate that the combination of UCN-01 and radiation can more specifically target resistant TP53 mutated cancer cells and spare TP53 wild-type normal cells. (C) 2002 by Radiation Research Society.
机构:
Bayer Healthcare, Global Drug Discovery, Berlin, Germany
Free Univ Berlin, Inst Chem Biochem, D-1000 Berlin, Germany
VTT Tech Res Ctr Finland, Turku, FinlandBayer Healthcare, Global Drug Discovery, Berlin, Germany
Winsel, Sebastian
Sommer, Anette
论文数: 0引用数: 0
h-index: 0
机构:
Bayer Healthcare, Global Drug Discovery, Berlin, GermanyBayer Healthcare, Global Drug Discovery, Berlin, Germany
Sommer, Anette
Eschenbrenner, Julia
论文数: 0引用数: 0
h-index: 0
机构:
Bayer Healthcare, Global Drug Discovery, Berlin, Germany
Tech Univ Berlin, Inst Biotechnol, Berlin, GermanyBayer Healthcare, Global Drug Discovery, Berlin, Germany
Eschenbrenner, Julia
Mittelstaedt, Kevin
论文数: 0引用数: 0
h-index: 0
机构:
Bayer Healthcare, Global Drug Discovery, Berlin, Germany
Univ Melbourne, Dept Med, Melbourne, Vic, AustraliaBayer Healthcare, Global Drug Discovery, Berlin, Germany
Mittelstaedt, Kevin
Klar, Ulrich
论文数: 0引用数: 0
h-index: 0
机构:
Bayer Healthcare, Global Drug Discovery, Berlin, GermanyBayer Healthcare, Global Drug Discovery, Berlin, Germany
Klar, Ulrich
Hammer, Stefanie
论文数: 0引用数: 0
h-index: 0
机构:
Bayer Healthcare, Global Drug Discovery, Berlin, GermanyBayer Healthcare, Global Drug Discovery, Berlin, Germany
Hammer, Stefanie
Hoffmann, Jens
论文数: 0引用数: 0
h-index: 0
机构:
Bayer Healthcare, Global Drug Discovery, Berlin, Germany
Max Delbruck Ctr Mol Med, Berlin, GermanyBayer Healthcare, Global Drug Discovery, Berlin, Germany